Business
China Licence received
China Licence received.
About this update from Tristel Plc
[{"type":"text","content":"\n \nRNS Number : 4596G Tristel PLC 12 May 2011 \n \n\nTristel plc \n(\"Tristel\" or \"the Company\")\nAIM: TSTL\n \nLicence to sell Stella decontamination system received in China\n \nTristel plc, the manufacturer of infection control, contamination control and hygiene products, announces that it has received the administrative licence that will enable the use of its Stella decontamination system in China.\n \nStella is a sophisticated micro-processor controlled tray in which medical instruments are immersed in Tristel's chlorine dioxide disinfectant. Hospitals can employ Stella at a fraction of the capital and running cost of the endoscope washers that are widely used as the only alternative to the age-old practice of placing instruments in a sink or simple plastic container. \n \nStella is particularly relevant to hospital departments such as urology, gynaecology, respiratory, cardiology and GI physiology. It deliberately cannot be used with the large flexible endoscopic instruments that are the focus of most of Tristel's competitors. \n \nTristel received regulatory approval for Stella last Autumn and the receipt of the licence enables its use by hospitals. The Company's China subsidiary, Shanghai Stella Medical Equipment Co. Ltd., has already appointed six distributors for the Stella system. These distributors purchased 30 Stella units between June and December 2010 for training and evaluation purposes. The Company has established its own sales force to sell directly in the Shanghai metropolitan area.\n \nOutside of China, Tristel has sold 63 Stella units in the United Kingdom, Belgium, Spain, Ireland, Italy, Dubai, New Zealand and Germany. In a clinical study recently concluded Stella has been subjected to a randomised single-blind comparison with the world's leading brand of instrument disinfectant used in one of the most widely used endoscope washers. Stella's efficacy has been shown to be the equivalent of the process to which it was compared, but it produced vast savings in cost and process time. The study is anticipated to be published later this year. \n \nPaul Swinney, Chief Executive of Tristel, said: \"We have been eagerly awaiting receipt of this licence for many months because Stella sales in China ha...